28.7% Weight Loss in New Retatrutide Study
Brad Stanfield
Dec 16, 2025
Episode description
A freshly published study demonstrated a whopping 28.7% weight loss over a 68-week time period from a drug called Retatrutide.
For weekly health research summaries and extra insights, sign up here 👉 https://drstanfield.com/pages/sign-up
💊 Supplements I Take: https://drstanfield.com/pages/my-supplements
💊MicroVitamin+ (Pro) Powder: https://drstanfield.com/products/microvitamin-plus
💊MicroVitamin Standard Capsules: https://drstanfield.com/products/microvitamin
Timestamps:
00:00 Retatrutide Triple Agonist
00:21 Innovation and Evolution of GLP-1 Medications
02:02 Adding GIP to GLP-1 Medications (Tirzepatide)
02:42 Adding Glucagon Receptor Agonists to GLP-1 and GIP
03:45 Phase 3 Trial Results of Retetrutide
05:03 Comparing Retatrutide with Ozempic and Tirzepatide
05:57 Safety Concerns and Side Effects of Retatrutide
08:52 Final Thoughts on Retatrutide & Key Takeaways
📜 Roadmap - how to look young & feel strong: https://drstanfield.com/pages/roadmap
✔️ Twitter: https://twitter.com/BradStanfieldMD
✔️ Patreon: https://www.patreon.com/bradstanfieldmd
Here are the links to the research papers referenced in the video:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4509428/
https://www.medclinrese.org/open-access/drug-discovery-and-development-of-semaglutide-and-tirzepatide-from-the-gila-monsters-heloderma-spp.pdf
https://www.sciencedirect.com/science/article/abs/pii/S2352154616300274
https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/
https://www.ncbi.nlm.nih.gov/sites/books/NBK279127/
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.868037/full
https://www.sciencedirect.com/science/article/abs/pii/S014067362301053X
https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
https://medical.lilly.com/us/products/answers/has-dysesthesia-been-reported-in-patients-taking-mounjaro-tirzepatide-256308
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Thumbnail by James Kelly
Video edited by Troy Young
Script by John Milliken
The links above are affiliate links, so I receive a small commission every time you use them to purchase a product. The content contained in this video, and its accompanying description, is not intended to replace viewers’ relationships with their own medical practitioner. Always speak with your doctor regarding the content of this channel, and especially before using any products, services, or devices discussed on this channel.
Mindsip insights from this episode:
Monitor retatrutide for dysesthesia risk in users
Nearly 21% of retatrutide users reported dysesthesia, a painful or tingling skin sensation, a side effect that is very uncommon with Ozempic or tirzepatide.
Reduce dropout rates by comparing retatrutide with Ozempic and tirzepatide
The discontinuation rate for retatrutide was an extraordinarily high 18%, compared to just 4.5% for Ozempic and 7% for tirzepatide.
Maximize weight loss with retatrutide's triple-action mechanism
The new weight loss drug retatrutide is a triple agonist, targeting GLP-1, GIP, and glucagon receptors to maximize weight loss effects.
Stop wasting money on ineffective GLP-1 supplements
Supplements claiming to increase GLP-1 are a waste of money because the body naturally breaks down GLP-1 within minutes.
Utilize GLP-1 medications from Gila monster venom for weight loss
The first long-lasting GLP-1 medications were developed from a chemical found in the venom of the Gila monster that resisted breakdown.
Clarify weight loss claims for retatrutide efficacy
The headline 29% weight loss for retatrutide was an 'efficacy estimate,' while the more realistic 'intention-to-treat' analysis showed a 23.7% loss, much closer to tirzepatide's 20.9%.
Choose tirzepatide over retatrutide for safer weight loss
Despite greater weight loss, retatrutide's significantly worse side effect profile means it is not recommended as a first-line option over tirzepatide.
